- Home
- SLNO
as 04-18-2025 1:43pm EST
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 2.3B | IPO Year: | 2014 |
| Target Price: | $95.75 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $36.61 - $74.00 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Soleno Therapeutics Inc. (SLNO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hirano Patricia C | SLNO | SEE REMARKS | Apr 1 '25 | Sell | $70.11 | 3,782 | $265,156.02 | 27,036 | |
| Pauls Matthew | SLNO | Director | Mar 28 '25 | Sell | $71.55 | 5,937 | $424,797.10 | 6,500 | |
| Mackaness James H | SLNO | CHIEF FINANCIAL OFFICER | Mar 27 '25 | Sell | $69.46 | 90,622 | $6,293,177.03 | 105,176 | |
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Mar 27 '25 | Sell | $68.58 | 699,095 | $47,271,960.10 | 776,302 | |
| Yen Kristen | SLNO | SEE REMARKS | Mar 27 '25 | Sell | $68.72 | 95,500 | $6,376,788.66 | 62,235 | |
| Hirano Patricia C | SLNO | SEE REMARKS | Mar 27 '25 | Sell | $69.39 | 156,315 | $10,709,353.03 | 27,036 | |
| Manning Meredith | SLNO | Chief Commercial Officer | Mar 27 '25 | Sell | $69.03 | 45,249 | $3,044,342.88 | 45,385 | |
| Vivo Opportunity, LLC | SLNO | 10% Owner | Mar 26 '25 | Sell | $68.07 | 1,833,557 | $124,449,124.20 | 4,458,294 |
Latest Soleno Therapeutics Inc. News
SLNO Breaking Stock News: Dive into SLNO Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Soleno Therapeutics Announces VYKAT(TM) XR Launch
MT Newswires
16 days ago
Soleno Therapeutics Insider Sold Shares Worth $265,156, According to a Recent SEC Filing
Simply Wall St.
18 days ago
High Growth Tech Stocks To Watch In The US April 2025
Argus Research
18 days ago
Daily – Vickers Top Buyers & Sellers for 04/01/2025
MT Newswires
18 days ago
Soleno Therapeutics Insider Sold Shares Worth $10,709,353, According to a Recent SEC Filing
MT Newswires
18 days ago
Soleno Therapeutics Insider Sold Shares Worth $1,013,627, According to a Recent SEC Filing
MT Newswires
18 days ago
Soleno Therapeutics Insider Sold Shares Worth $6,376,789, According to a Recent SEC Filing
MT Newswires
18 days ago
Soleno Therapeutics Insider Sold Shares Worth $3,044,343, According to a Recent SEC Filing
Compare SLNO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLNO Soleno Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.